How large is the chronic liver diseases therapeutics market, and what is its growth trajectory?
The chronic liver disease therapeutics market size has grown rapidly in recent years. It will grow from $14.38 billion in 2024 to $15.92 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historical period can raise the incidence of viral hepatitis, increase obesity rates, age the population, grow awareness of liver health, and increase patient access to treatment.
The chronic liver disease therapeutics market size is expected to see rapid growth in the next few years. It will grow to $23.83 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast increased focus on personalized medicine, growing the pipeline of novel therapies, expanding telemedicine and digital health solutions, and rising demand for liver disease prevention programs, as well as the rising incidence of viral hepatitis. Major trends: integration of artificial intelligence in diagnostics, biologics and gene therapies, non-invasive treatment options, combination therapies, and expansion of patient-centric care models.
Get Your Free Sample of The Global Chronic Liver Diseases Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp
What are the key forces behind the chronic liver diseases therapeutics market’s growth in recent years?
Increasing alcohol consumption is expected to propel the growth of the chronic liver disease therapeutics market going forward. Alcohol consumption is the intake of beverages containing ethanol, ranging from moderate to excessive use, with potential health impacts. Increasing alcohol consumption is due to growing social acceptance, rising incomes, and greater accessibility worldwide. Chronic liver disease therapeutics help manage liver damage caused by excessive alcohol consumption, slowing disease progression and improving liver function. For instance, in June 2024, according to the First Citizens Bank, a US financial institution, there was a 1.2% increase in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022. Additionally, in December 2023, according to the report published by Kirin Holdings Company Limited, a Japan-based beverage company, it was noted that around 192.1 million kiloliters of beer were consumed in 2022, reflecting a 2.9% increase from the previous year. Therefore, the increasing alcohol consumption is driving the growth of the chronic liver disease therapeutics market.
What are the major segments of the chronic liver diseases therapeutics market?
The chronic liver diseases therapeutics market covered in this report is segmented –
1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy
2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals
2) By Immunosuppressants: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors
3) By Vaccines: Hepatitis A Vaccine, Hepatitis B Vaccine, Combination Hepatitis Vaccines
4) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin
5) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone
6) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies
7) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents
Order your report now for swift delivery
Which companies dominate the chronic liver diseases therapeutics market?
Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.
What major trends will shape the chronic liver diseases therapeutics market during the forecast period?
Major companies operating in the chronic liver diseases therapeutics market are focused on developing advanced innovations, such as RNA therapies to target underlying genetic and molecular mechanisms, offering more effective and personalized treatment options. RNA therapies are advanced medical treatments that use RNA molecules to regulate gene expression or protein production, aiming to treat or prevent diseases by targeting specific genetic mechanisms. For instance, in May 2022, Ochre Bio, a UK-based biotech company, launched its innovative ‘Liver ICU’ research facility at BioLabs@NYULangone, a biopharma incubator in New York City. This state-of-the-art site assesses the effectiveness of next-generation RNA therapeutics using whole human livers sustained on perfusion machines. By leveraging discarded donor livers for research, the facility aims to accelerate drug development timelines and improve the precision of liver treatment studies by replicating human physiological conditions.
What are the key regional dynamics of the chronic liver diseases therapeutics market, and which region leads in market share?
North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Chronic Liver Diseases Therapeutics Market Report 2025 Offer?
The chronic liver diseases therapeutics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Chronic liver disease therapeutics refers to the medical treatments and interventions aimed at managing long-term liver conditions. These therapies focus on slowing disease progression, alleviating symptoms, and improving liver function through medications, lifestyle changes, and, in some cases, advanced procedures.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21145
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
